ISU Abxis Past Earnings Performance
Past criteria checks 0/6
ISU Abxis has been growing earnings at an average annual rate of 35.3%, while the Biotechs industry saw earnings growing at 1.6% annually. Revenues have been growing at an average rate of 24.6% per year.
Key information
35.3%
Earnings growth rate
39.7%
EPS growth rate
| Biotechs Industry Growth | 11.7% |
| Revenue growth rate | 24.6% |
| Return on equity | -8.5% |
| Net Margin | -9.6% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
Why Investors Shouldn't Be Surprised By ISU Abxis Co., Ltd.'s (KOSDAQ:086890) 26% Share Price Plunge
Nov 14
ISU Abxis (KOSDAQ:086890) Takes On Some Risk With Its Use Of Debt
Nov 12ISU Abxis Co., Ltd.'s (KOSDAQ:086890) Intrinsic Value Is Potentially 84% Above Its Share Price
Aug 07ISU Abxis (KOSDAQ:086890) Takes On Some Risk With Its Use Of Debt
Jun 10Benign Growth For ISU Abxis Co., Ltd. (KOSDAQ:086890) Underpins Its Share Price
Mar 12We Think ISU Abxis (KOSDAQ:086890) Has A Fair Chunk Of Debt
Feb 17
ISU Abxis'(KOSDAQ:086890) Share Price Is Down 21% Over The Past Three Years.
Dec 25Revenue & Expenses Breakdown
How ISU Abxis makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 62,054 | -5,970 | 15,975 | 11,919 |
| 31 Mar 24 | 64,057 | -8,089 | 17,298 | 13,871 |
| 31 Dec 23 | 54,306 | 3,611 | 14,483 | 15,210 |
| 30 Sep 23 | 46,883 | -3,292 | 14,966 | 17,466 |
| 30 Jun 23 | 48,237 | -4,734 | 15,551 | 17,104 |
| 31 Mar 23 | 42,317 | -6,582 | 13,748 | 15,728 |
| 31 Dec 22 | 41,170 | -7,247 | 13,744 | 13,368 |
| 30 Sep 22 | 39,649 | 307 | 12,393 | 9,164 |
| 30 Jun 22 | 32,233 | -1,766 | 11,103 | 8,494 |
| 31 Mar 22 | 29,324 | -696 | 10,830 | 7,630 |
| 31 Dec 21 | 28,018 | 830 | 10,597 | 7,568 |
| 30 Sep 21 | 29,456 | -16,933 | 8,239 | 12,079 |
| 30 Jun 21 | 27,184 | -16,149 | 10,064 | 10,037 |
| 31 Mar 21 | 25,985 | -19,125 | 9,772 | 11,545 |
| 31 Dec 20 | 25,607 | -19,865 | 10,191 | 12,650 |
| 30 Sep 20 | 22,931 | -18,822 | 11,758 | 11,411 |
| 30 Jun 20 | 21,437 | -20,073 | 8,947 | 13,965 |
| 31 Mar 20 | 21,151 | -18,937 | 9,346 | 12,771 |
| 31 Dec 19 | 21,019 | -17,816 | 9,125 | 12,595 |
| 30 Sep 19 | 20,217 | -14,088 | 9,568 | 10,733 |
| 30 Jun 19 | 20,034 | -12,117 | 9,294 | 10,784 |
| 31 Mar 19 | 18,094 | -13,507 | 9,337 | 10,933 |
| 31 Dec 18 | 16,746 | -12,989 | 9,199 | 10,099 |
| 30 Sep 18 | 15,375 | -12,825 | 8,681 | 10,687 |
| 30 Jun 18 | 16,239 | -12,278 | 8,805 | 9,939 |
| 31 Mar 18 | 18,159 | -9,480 | 7,805 | 9,978 |
| 31 Dec 17 | 19,459 | -8,729 | 7,625 | 9,885 |
| 30 Sep 17 | 19,373 | -8,102 | 7,077 | 10,518 |
| 30 Jun 17 | 19,943 | -6,947 | 6,857 | 10,243 |
| 31 Mar 17 | 19,687 | -5,384 | 6,811 | 8,601 |
| 31 Dec 16 | 19,055 | -4,367 | 6,404 | 7,673 |
| 30 Sep 16 | 19,096 | -2,918 | 6,381 | 5,338 |
| 30 Jun 16 | 15,694 | -6,977 | 5,772 | 4,956 |
| 31 Mar 16 | 12,506 | -9,161 | 5,328 | 5,294 |
| 31 Dec 15 | 11,471 | -9,773 | 5,257 | 5,340 |
| 30 Sep 15 | 8,901 | -9,978 | 4,858 | 4,649 |
| 30 Jun 15 | 8,211 | -8,294 | 4,872 | 4,534 |
| 31 Mar 15 | 7,529 | -10,718 | 5,023 | 4,254 |
| 31 Dec 14 | 7,097 | -11,198 | 5,151 | 4,293 |
| 30 Sep 14 | 7,893 | -10,412 | 5,203 | 3,881 |
| 30 Jun 14 | 7,727 | -10,576 | 5,355 | 4,426 |
| 31 Mar 14 | 8,746 | -7,607 | 5,645 | 4,278 |
| 31 Dec 13 | 8,164 | -8,191 | 6,070 | 4,202 |
Quality Earnings: A086890 is currently unprofitable.
Growing Profit Margin: A086890 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: A086890 is unprofitable, but has reduced losses over the past 5 years at a rate of 35.3% per year.
Accelerating Growth: Unable to compare A086890's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: A086890 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-1.3%).
Return on Equity
High ROE: A086890 has a negative Return on Equity (-8.48%), as it is currently unprofitable.